STOK Stoke Therapeutics, Inc.
FY2025 10-K
Stoke Therapeutics, Inc. (STOK) filed its fiscal year 2025 10-K annual report with the SEC on Mar 16, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: RNA-based medicines using proprietary TANGO platform to upregulate protein expression for treating severe genetic diseases
- • New focus: Phase 3 study of zorevunersen for Dravet syndrome initiated May 2025, plus Phase 1 study of STK-002 for autosomal dominant optic atrophy
Management Discussion & Analysis
- • Revenue $184.4M in 2025 vs $36.6M in 2024, up $147.8M mainly from Biogen collaboration ($168.3M in 2025) offset by Acadia decline
- • Net loss $6.9M in 2025 vs $89.0M in 2024; operating loss improved to $20.6M from $101.4M; operating margin approx. -11.2% vs -277.1%
Risk Factors
- • Regulatory risk from FDA clinical holds: partial hold on zorevunersen doses removed, future holds possible delaying development
- • Macroeconomic exposure: potential impacts from inflation, fluctuating interest rates, tariffs, recessions, and government shutdowns on operations
Get deeper insights on Stoke Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.